Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Study hypothesis is that aprepitant is more effective than desloratadine in relieving
pruritus caused by EGFR TKIs. Primary endpoint is the effective rate of pruritus, effective
treatment defined as visual analogue scale (VAS) decrease ≥ 50% after treatment compared to
baseline score. 130 NSCLC patients undertaken EGFR-TKI and suffer from moderate or severe
pruritus (VAS score ≥ 4) will be enrolled in this study, and stratified (gender, VAS 4-6 or
7-10, and 2nd generation TKI or non 2nd generation) randomized (1:1) into aprepitant or
desloratadine treatment. VAS investigation will be taken once a week to treatment end (4
weeks).